A Phase 3 interventional study of Oxymetazoline HCL Cream 1.0% and Vehicle to Oxymetazoline HCL Cream in Erythema and Rosacea, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Erythema with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Erythema · United States.
Among the 55 studies in Erythema with a site in United States, this one has the largest enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2014, is one of 5 in phase 3, and was the 16th registered.
131 studies on the registry are indexed under Erythema; 17 are open to participants now.
Browse Erythema studies →8 of the 55 studies in Erythema with a site in United States are open now. Recruiting first, the newest first:
Medicines Development for Global Health · Sites in United States, Benin, Côte D'Ivoire and 3 more countries
Ages 18+
Good Molecules, LLC · Sites in United States
Ages 18–75 · Healthy volunteers
University of Nevada, Las Vegas · Sites in United States
Ages 18+
Acorn Biolabs Inc. · Sites in United States, Canada
Ages 18+ · Healthy volunteers
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Erythema studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 445 is above the median of 50 across 114 interventional studies indexed under Erythema.
Median enrollment 52 across the 52 interventional studies, 104 across the 3 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 7 studies filed under Erythema — fewer than ten, so there is no comparison to draw.
4 of the studies in Erythema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07172659Medicines Development for Global HealthEfficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction | 2027-01 |
| NCT06477172Acorn Biolabs Inc.Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures | 2027-02 |
| NCT07789639Good Molecules, LLCA Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use | 2027-02-24 |
| NCT02876107M.D. Anderson Cancer CenterCarboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Erythema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Moderate to severe persistent facial erythema associated with rosacea.
Exclusion Criteria:
Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
Drug: Oxymetazoline HCL Cream 1.0%
Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
Drug: Vehicle to Oxymetazoline HCL Cream
Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales
The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29. Baseline was defined as the measurement at pre-dose on Day 1.
Time frame: Baseline, Day 29 (Hours 3, 6, 9 and 12)
Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on SSA at Hours 3, 6, 9 and 12 on Day 29
The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29.
Time frame: Baseline, Day 29 (Hours 3, 6, 9 and 12)
Percent Change From Baseline on Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA) at Hours 3, 6, 9 and 12 on Day 29
DIA of photographs was used to assess rosacea facial redness and was defined as percentage of facial area occupied by redness. A higher value in the percentage of facial area occupied by facial redness indicated more redness. A negative/ lower number percent change from Baseline indicates improvement.
Time frame: Baseline, Day 29 (Hours 3, 6, 9 and 12)
Percentage of Participants Satisfied or Very Satisfied on Item #9 of Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR) at Hours 3, 6, 9 and 12 on Day 29
Participants assessed their treatment satisfaction by answering Item #9 of the SAT-RFR: "Right now, how satisfied are you with the effect your study medication had on your facial redness?" using a 5-point scale where 0= very dissatisfied, 1=dissatisfied, 2=neither satisfied or dissatisfied, 3=satisfied, or 4=very satisfied. The percentage of participants who answered Satisfied or Very Satisfied is reported.
Time frame: Day 29 (Hours 3, 6, 9 and 12)
Change From Baseline on the Symptom Assessment for Rosacea Facial Redness (SA-RFR) Item # 4 at Hours 3, 6, 9 and 12 on Day 29
Participants assessed the burning sensation associated with rosacea facial redness by answering Item #4 of the SA-RFR: "Right now, how much does your face burn because of your facial redness?" using a 5-point scale where 0=less severe to 4=severe. A negative change from Baseline indicates improvement.
Time frame: Baseline, Day 29 (Hours 3, 6, 9 and 12)
Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1
The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement.
Time frame: Baseline, Day 1 (Hour 1)
| Milestone | Oxymetazoline HCL Cream 1.0% | Vehicle |
|---|---|---|
| Started | 224 | 221 |
| Completed | 213 | 216 |
| Not completed | 11 | 5 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Personal reasons | 1 | 2 |
| Withdrew: Other miscellaneous reasons | 2 | 0 |
The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29. Baseline was defined as the measurement at pre-dose on Day 1.
| percentage of participants | Oxymetazoline HCL Cream 1.0% | Vehicle |
|---|---|---|
| Day 29 (Hour 3) | 14.3 | 7.4 |
| Day 29 (Hour 6) | 13.4 | 4.8 |
| Day 29 (Hour 9) | 15.5 | 8.5 |
| Day 29 (Hour 12) | 12.3 | 6.1 |
The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29.
| percentage of participants | Oxymetazoline HCL Cream 1.0% | Vehicle |
|---|---|---|
| Day 29 (Hour 3) | 24.1 | 15.8 |
| Day 29 (Hour 6) | 24.8 | 14.7 |
| Day 29 (Hour 9) | 22.0 | 16.0 |
| Day 29 (Hour 12) | 23.7 | 15.8 |
DIA of photographs was used to assess rosacea facial redness and was defined as percentage of facial area occupied by redness. A higher value in the percentage of facial area occupied by facial redness indicated more redness. A negative/ lower number percent change from Baseline indicates improvement.
| percent change in area of redness | Oxymetazoline HCL Cream 1.0% | Vehicle |
|---|---|---|
| Day 29 (Hour 3) | -25.70 ± 144.776 | 0.00 ± 225.452 |
| Day 29 (Hour 6) | -15.95 ± 170.735 | 2.25 ± 198.138 |
| Day 29 (Hour 9) | -10.95 ± 131.933 | 5.15 ± 200.530 |
| Day 29 (Hour 12) | -9.60 ± 145.898 | 1.00 ± 195.291 |
Participants assessed their treatment satisfaction by answering Item #9 of the SAT-RFR: "Right now, how satisfied are you with the effect your study medication had on your facial redness?" using a 5-point scale where 0= very dissatisfied, 1=dissatisfied, 2=neither satisfied or dissatisfied, 3=satisfied, or 4=very satisfied. The percentage of participants who answered Satisfied or Very Satisfied is reported.
| percentage of participants | Oxymetazoline HCL Cream 1.0% | Vehicle |
|---|---|---|
| Day 29 (Hour 3) | 54.3 | 34.1 |
| Day 29 (Hour 6) | 49.3 | 32.3 |
| Day 29 (Hour 9) | 49.8 | 33.6 |
| Day 29 (Hour 12) | 47.5 | 36.4 |
Participants assessed the burning sensation associated with rosacea facial redness by answering Item #4 of the SA-RFR: "Right now, how much does your face burn because of your facial redness?" using a 5-point scale where 0=less severe to 4=severe. A negative change from Baseline indicates improvement.
| score on a scale | Oxymetazoline HCL Cream 1.0% | Vehicle |
|---|---|---|
| Day 29 (Hour 3) | -1.8 ± 0.97 | -1.6 ± 0.93 |
| Day 29 (Hour 6) | -1.8 ± 0.93 | -1.6 ± 0.91 |
| Day 29 (Hour 9) | -1.8 ± 0.91 | -1.7 ± 0.96 |
| Day 29 (Hour 12) | -1.8 ± 0.92 | -1.7 ± 0.91 |
The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement.
| percentage of participants | Oxymetazoline HCL Cream 1.0% | Vehicle |
|---|---|---|
| Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1 | 29.7 | 16.8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxymetazoline HCL Cream 1.0% | — | 3/223 (1.3%) | 0/223 (0%) |
| Vehicle | — | 2/221 (0.9%) | 0/221 (0%) |
| Event | Oxymetazoline HCL Cream 1.0% | Vehicle |
|---|---|---|
| GoitreEndocrine disorders | 0/223 | 1/221 |
| HyperparathyroidismEndocrine disorders | 0/223 | 1/221 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/223 | 1/221 |
| ConcussionInjury, poisoning and procedural complications | 0/223 | 1/221 |
| Rib fractureInjury, poisoning and procedural complications | 0/223 | 1/221 |
| Spinal fractureInjury, poisoning and procedural complications | 0/223 | 1/221 |
| Traumatic liver injuryInjury, poisoning and procedural complications | 0/223 | 1/221 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/223 | 1/221 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/223 | 0/221 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/223 | 0/221 |
| Age, Customized(participants) | Oxymetazoline HCL Cream 1.0% | Vehicle | Total |
|---|---|---|---|
| 18-64 years | 198 | 193 | 391 |
| >=65 years | 26 | 28 | 54 |
| Sex: Female, Male(Participants) | Oxymetazoline HCL Cream 1.0% | Vehicle | Total |
|---|---|---|---|
| Female | 177 | 173 | 350 |
| Male | 47 | 48 | 95 |
The record gives a start of Jun 2014, a primary completion of Apr 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxymetazoline